Abstract: The disclosure provides recombinant polypeptides for treating or preventing viral infection comprising an immunoglobulin Fc fragment and at least one viral receptor or fragment thereof. Also provided are RNA molecules, therapeutic compositions, and expression systems comprising such recombinant polypeptides, along with methods of preventing or treating a viral infection in a subject in need thereof, comprising administering such recombinant polypeptides to a subject or patient.

Abstract: The disclosure provides methods for treating or preventing coronavirus infection comprising administration of a therapeutically effective amount of lactoferrin or a therapeutically effective amount of a protein fusion comprising recombinant lactoferrin fused to the receptor binding domain of the SARS-CoV-2 spike protein. Also provided are methods for treating or preventing SARS-CoV-2 infection comprising co-administration of a therapeutically effective amount of lactoferrin and a second drug treatment, such as ivermectin. Also provided are methods for treating or preventing SARS-CoV-2 infection comprising co-administration of a therapeutically effective amount of lactoferrin and a second drug treatment, such as ivermectin.

Abstract: The disclosure provides recombinant polypeptides for treating or preventing viral infection comprising an immunoglobulin Fc fragment and at least one viral receptor or fragment thereof. Also provided are RNA molecules, therapeutic compositions, and expression systems comprising such recombinant polypeptides, along with methods of preventing or treating a viral infection in a subject in need thereof, comprising administering such recombinant polypeptides to a subject or patient.

Abstract: The disclosure provides recombinant polypeptides for treating or preventing viral infection comprising an immunoglobulin Fc fragment and at least one viral receptor or fragment thereof. Also provided are RNA molecules, therapeutic compositions, and expression systems comprising such recombinant polypeptides, along with methods of preventing or treating a viral infection in a subject in need thereof, comprising administering such recombinant polypeptides to a subject or patient.

Abstract: Described herein are systems and methods for the quantitative analysis of a sample comprising glycated hemoglobin. Also described herein are systems and methods for assaying a sample to quantitatively determine the percentage of glycated hemoglobin in the sample, for example, in a blood sample. The methods and systems described herein may be used in a point-of-care device as well as in other in vitro diagnostic devices.

Abstract: Described herein are systems and methods for assaying a sample to quantitatively determine the percentage of glycated hemoglobin in the sample.

Abstract: Described herein are systems and methods for assaying a sample to quantitatively determine the percentage of glycated hemoglobin in the sample.

Abstract: The subject invention provides a site-specific integration system and methods for generating eukaryotic cells lines for protein production. The provided system includes a first site-specifically integrating target vector and a second site-specifically integrating donor vector comprising a gene of interest. Also provided are mammalian cell lines produced by the subject methods and systems, as well as kits that include the subject systems.

Abstract: Described herein are systems and methods for assaying a sample to quantitatively determine the percentage of glycated hemoglobin in the sample.

Abstract: Devices, systems, and methods for detecting the presence of one or more analytes in a sample are described. In some variations, a test strip may be used to detect and/or analyze one or more analytes in a sample. In certain variations, a test strip configured to receive a sample for detection of an analyte therein may comprise a substrate and a coating on a portion of the substrate, the coating comprising a combination of a first analyte capture agent configured to bind to a first analyte and a second analyte capture agent configured to bind to a second analyte that is different from the first analyte.

Abstract: The present invention relates to a lateral flow assay and system, including a test strip, for detection and quantification of analytes in samples, such as samples containing cells and fluid, where the assay is volume independent, and the sample size is less than about 100 ?l, where the test strip includes a first membrane such as a sample filter, that is in capillary contact with an optional second membrane, such as a fluid collector, the second membrane, if present is in capillary contact with an optional third membrane, such as a conjugate pad containing a mobilizable detectable agent, or with a fourth membrane, which is a chromatographic strip, which optionally contains a mobilizable detectable agent, all such membranes being in fluid contact with a fifth membrane, such as a buffer pad, a sixth membrane, such as an absorbent pad, optionally a seventh membrane, which is also an absorbent pad, a capture band for capturing the analyte and at least one control band, or alternatively, the chromatographic strip

Abstract: A telephone line shunt for disabling incoming and outgoing calls to or from a telephone line. The device attaches to a single outlet or telephone such that the line is unavailable to devices attached to it from any other location. A shunt short circuits the ring and pitch lines of a conventional telephone line to inhibit a dial tone for outgoing calls while simultaneously creating the appearance of a line busy status for incoming calls. The shunt is inserted into any standard telephone wall jack to inhibit line availability, and removed to restore line availability. The shunt can be implemented by a simple wire shunt embedded in a modified plug for an RJ-11 jack. Alternatively, the shunt can be controlled by activation switches on a wall receptacle, on a telephone hand set, and on a telephone/clock radio. An optional remote control allows switching of the shunt. The shunt control mechanism may also used a password system to control access to the shunt.

Abstract: A telephone line shunt for disabling incoming and outgoing calls to or from a telephone line. The device attaches to a single outlet or telephone such that the line is unavailable to devices attached to it from any other location. A shunt short circuits the ring and pitch lines of a conventional telephone line to inhibit a dial tone for outgoing calls while simultaneously creating the appearance of a line busy status for incoming calls. The shunt is inserted into any standard telephone wall jack to inhibit line availability, and removed to restore line availability. The shunt can be implemented by a simple wire shunt embedded in a modified plug for an RJ-11 jack. Alternatively, the shunt can be controlled by activation switches on a wall receptacle, on a telephone hand set, and on a telephone/clock radio. An optional remote control allows switching of the shunt. The shunt control mechanism may also used a password system to control access to the shunt.

Abstract: The present invention relates to chimeric molecules containing component molecules that are linked together in a non-naturally occurring manner where the linker contains at least one enzyme cleavage site, and the enzyme cleavage site is engineered to be cleaved by an enzyme in a treated subject. The present invention also relates to compositions and kits containing the chimeric molecules, methods of making the chimeric molecules in a production host, methods of using the present chimeric molecules for diagnostic, prophylactic, therapeutic, and nutritional purposes in subjects requiring such.

Abstract: A breast carcinoma tyrosine phosphoprotein, DDR (Discoidin Domain Receptor), that defines a novel class of receptor tyrosine kinases is presented. The DDR cDNA predicts a polypeptide C-terminal tyrosine kinase domain and an N-terminal domain similar to the Dictyostelium discoideum lectin discoidin I. These domains are connected by an extraordinary hydrophilic proline/glycine-rich domain, which is interrupted by a predicted transmembrane sequence. This extended proline/glycine-rich region suggests an unusual geometry of interaction with ligand or substrates. Discoidin I-type domains may interact with specific cell surface molecules.

Abstract: A breast carcinoma tyrosine phosphoprotein, DDR (Discoidin Domain Receptor), that defines a novel class of receptor tyrosine kinases is presented. The DDR cDNA predicts a polypeptide C-terminal tyrosine kinase domain and an N-terminal domain similar to the Dictyostelium discoideum lectin discoidin I. These domains are connected by an extraordinary hydrophilic proline/glycine-rich domain, which is interrupted by a predicted transmembrane sequence. This extended proline/glycine-rich region suggests an unusual geometry of interaction with ligand or substrates. Discoidin I-type domains may interact with specific cell surface molecules.

Abstract: The present invention relates to synthesis of HBSAg in yeast. Yeast expression vectors comprising a yeast promoter, ADH1, have been constructed. The region of the HBV genome coding for the S-protein, excluding a possible 163 amino acid presequence, has been transferred to the yeast expression vector. Using the described yeast vector, the successful synthesis of HBSAg by yeast has been achieved. The product is antigenic (reactive with anti-HBSAg), and a substantial portion is found associated with particles identical in electron microscopic appearance to those found in the serum of HBV-infected patients and in Alexander cells but having a smaller particle size diameter. The HBSAg synthesized by yeast has identical sedimentation behavior to purified, naturally occurring HBSAg particles purified from Alexander cells as measured by sucrose gradient sedimentation.

Abstract: The present invention relates to synthesis of HBsAg in yeast. Yeast expression vectors comprising a yeast promoter, ADH1, have been constructed. The region of the HBV genome coding for the S-protein, excluding a possible 163 amino acid presequence, has been transferred to the yeast expression vector. Using the described yeast vector, the successful synthesis of HBsAg by yeast has been achieved. The product is antigenic (reactive with anti-HBsAg), and a substantial portion is found associated with particles identical in electron microscopic appearance to those found in the serum of HBV-infected patients and in Alexander cells but having a smaller particle size diameter. The HBSAg synthesized by yeast has identical sedimentation behavior to purified, naturally-occurring HBsAq particles purified from Alexander cells as measured by sucrose gradient sedimentation.

Abstract: The invention provides for a postinfection HIV vaccination therapy having a therapeutic goal of eliminating HIV in the patient. The therapy directs administration of an agent to reduce the viral load of a patient with a measurable viral load of HIV, administration of an agent that induces an increase in production of the patient's CD4 T-cells, and administration of a vaccine capable of stimulating the patient to produce CTLs targeted to HIV-infected cells.

Abstract: A method to obtain selected individual peptides or families thereof which have a target property and optionally to determine the amino acid sequence of a selected peptide or peptides to permit synthesis in practical quantities is disclosed. In general outline, the method of the invention comprises synthesizing a mixture of randomly or deliberately generated peptides using standard synthesis techniques, but adjusting the individual concentrations of the components of a mixture of sequentially added amino acids according to the coupling constants for each amino acid/amino acid coupling. The subgroup of peptides having the target property can then be selected, and either each peptide isolated and sequenced, or analysis performed on the mixture to permit its composition to be reproduced. Also included in the invention is an efficient method to determine the relevant coupling constants.